This page lets you merge the Novartis P&L with another company to see the potential impact of M&A.
Synergies are modelled by default as 10%/15%/20% of the acquisition SGA+RND costs in years 1/2/3+ starting from 2022 and taxed at Novartis standalone rates. You can choose your own numbers.
Everything is modelled in USD at current FX rates.
No matches found...
Custom Synergies ($m):
This feature is only available to DRUGANALYST subscribers